* Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected
to show no change in quarterly revenue when it reports
results on July 31 (estimated).
*
* Refinitiv's mean analyst estimate for Phathom
Pharmaceuticals
Inc is for a loss of 100 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $18.5, above its last closing price
of $14.07.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -1.23 -1.26 -0.89 Beat 29.4
Dec. 31 2023 -1.34 -1.35 -1.33 Beat 1.6
Sep. 30 2022 -1.32 -1.32 -1.32 Met -0.2
Jun. 30 2022 -0.99 -1.03 -1.33 Missed -29.1
Mar. -0.98 -0.97 -1.07 Missed -10.5
31 2022
Dec. 31 2021 -1.05 -1.03 -0.95 Beat 7.6
Sep. 30 2021 -1.01 -0.98 -0.98 Met 0
Jun. 30 2021 -1.07 -1.07 -1.00 Beat 6.4
This summary was machine generated July 28 at 13:43 GMT. All
figures in US dollars unless otherwise stated